ArticleOncogene2021
Genomic and transcriptomic profiling of hepatoid adenocarcinoma of the stomach.
Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinicopathological features of hepatoid adenocarcinoma and non-hepatoid adenocarcinoma of the stomach: A systematic review and meta-analysis.Cancer medicine · 2024Pooled it
- Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach.International journal of biological sciences · 2022Pooled it
- [Novel clinical insights and frontier issues in alpha- fetoprotein-producing gastric cancer].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Review
- [Conversion therapy for hepatoid adenocarcinoma of the stomach: A case report].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
- Diagnostic dilemmas in hepatoid adenocarcinoma of the stomach: Navigating clinical and pathological loopholes.World journal of methodology · 2026Review
- A Clinical Guidance for the Management of Patients With Hepatoid Adenocarcinoma and A Case Series.Cancer medicine · 2026Review
- A case report of primary hepatoid adenocarcinoma of the vagina and literature review.Frontiers in oncology · 2026Article
- Case Report: Metastatic duodenal hepatoid adenocarcinoma: a rare pathology with exceptional response to dual immune checkpoint blockade.Frontiers in oncology · 2026Article
- Morphologic and Immunophenotypic Spectrum of 11 Gastric Cancers with Elevated Serum Alpha-Fetoprotein: Emphasis on Hepatoid or Enteroblastic Differentiation.International journal of general medicine · 2026Article
- Case Report: AFP-producing gastric hepatoid adenocarcinoma with multiple liver metastases - integrating quantitative imaging and diagnostic decision analysis.Frontiers in oncology · 2026Article
- Hepatoid adenocarcinoma of the stomach and non-hepatoid alpha-fetoprotein-producing gastric cancer exhibit a high degree of molecular similarity.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- The value of translational therapy in the treatment of advanced hepatoid adenocarcinoma of stomach.BMC cancer · 2025Article
- Predictive factors for neoadjuvant combined immunotherapy in gastric adenocarcinoma: Focusing on the primitive enterocyte phenotype and PVR.British journal of cancer · 2025Article
- Immune evasion strategies in AFP-producing gastric carcinoma: characterized by HLA-G expression and HLA class I deficiency.Virchows Archiv : an international journal of pathology · 2025Article
- Case report: Spatiotemporal HER2 heterogeneity in AFP-producing gastric cancer: navigating long-term survival with molecularly-guided therapy in a refractory case.Frontiers in immunology · 2025Article
- Targeting amino acid metabolism to inhibit gastric cancer progression and promote anti-tumor immunity: a review.Frontiers in immunology · 2025Review
- Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IVFrontiers in immunology · 2025Observational
- [TIM3+CD8+ T Cell Expression and Clinical Significance in the Central and Non-central Tumor Microenvironment of Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Article
- Development of dynamic nomogram for predicting cancer-specific survival in hepatoid adenocarcinoma: A comprehensive SEER-based population analysis.Biomolecules & biomedicine · 2024Article
- Recent developments in immunotherapy for gastrointestinal tract cancers.Journal of hematology & oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatoid adenocarcinoma of the stomach (HAS), a rare subtype of gastric cancer (GC), has a low incidence but a high mortality rate. Little is known about the molecular features of HAS. Here we applied whole-exome sequencing (WES) on 58 tumours and the matched normal controls from 54 HAS patients, transcriptome sequencing on 30 HAS tumours, and single-cell RNA sequencing (scRNA-seq) on one HAS tumour. Our results reveal that the adenocarcinomatous component and hepatocellular-like component of the same HAS tumour originate monoclonally, and HAS is likely to initiate from pluripotent precursor cells. HAS has high stemness and high methionine cycle activity compared to classical GC. Two genes in the methionine cycle, MAT2A, and AHCY are potential targets for HAS treatments. We provide the first integrative genomic profiles of HAS, which may facilitate its diagnosis, prognosis, and treatment.
Indexed as
Identifiers
34326469What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.